HOFFMANN, V.S., M. BACCARANI, J. HASFORD, D. LINDOERFER, S. BURGSTALLER, D. SERTIC, P. COSTEAS, Jiří MAYER, K. INDRAK, H. EVERAUS, P. KOSKENVESA, J. GUILHOT, G. SCHUBERT-FRITSCHLE, F. CASTAGNETTI, F. DI RAIMONDO, S. LEJNIECE, L. GRISKEVICIUS, N. THIELEN, T. SACHA, A. HELLMANN, A.G. TURKINA, A. ZARITSKEY, A. BOGDANOVICH, Z. SNINSKÁ, I. ZUPAN, J.L. STEEGMANN, B. SIMONSSON, R.E. CLARK, A. COVELLI, G. GUIDI and R. HEHLMANN. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia. London: Nature Publishing Group, 2015, vol. 29, No 6, p. 1336-1343. ISSN 0887-6924. Available from: https://dx.doi.org/10.1038/leu.2015.73.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries
Authors HOFFMANN, V.S. (276 Germany), M. BACCARANI (380 Italy), J. HASFORD (276 Germany), D. LINDOERFER (276 Germany), S. BURGSTALLER (40 Austria), D. SERTIC (191 Croatia), P. COSTEAS (196 Cyprus), Jiří MAYER (203 Czech Republic, guarantor, belonging to the institution), K. INDRAK (203 Czech Republic), H. EVERAUS (233 Estonia), P. KOSKENVESA (246 Finland), J. GUILHOT (250 France), G. SCHUBERT-FRITSCHLE (276 Germany), F. CASTAGNETTI (380 Italy), F. DI RAIMONDO (380 Italy), S. LEJNIECE (428 Latvia), L. GRISKEVICIUS (440 Lithuania), N. THIELEN (528 Netherlands), T. SACHA (616 Poland), A. HELLMANN (616 Poland), A.G. TURKINA (643 Russian Federation), A. ZARITSKEY (643 Russian Federation), A. BOGDANOVICH (688 Serbia), Z. SNINSKÁ (703 Slovakia), I. ZUPAN (705 Slovenia), J.L. STEEGMANN (724 Spain), B. SIMONSSON (752 Sweden), R.E. CLARK (826 United Kingdom of Great Britain and Northern Ireland), A. COVELLI (380 Italy), G. GUIDI (380 Italy) and R. HEHLMANN (276 Germany).
Edition Leukemia, London, Nature Publishing Group, 2015, 0887-6924.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 12.104
RIV identification code RIV/00216224:14110/15:00084395
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1038/leu.2015.73
UT WoS 000355615000012
Keywords in English CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; HEMATOLOGIC MALIGNANCIES; IMATINIB TREATMENT; INTERFERON-ALPHA; PROGNOSTIC SCORE; WORKING PARTY; FRONTLINE; SURVIVAL; THERAPY
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 26/10/2015 13:16.
Abstract
This population-based registry was designed to provide robust and updated information on the characteristics and the epidemiology of chronic myeloid leukemia (CML). All cases of newly diagnosed Philadelphia positive, BCR-ABL1+ CML that occurred in a sample of 92.5 million adults living in 20 European countries, were registered over a median period of 39 months. 94.3% of the 2904 CML patients were diagnosed in chronic phase (CP). Median age was 56 years. 55.5% of patients had comorbidities, mainly cardiovascular (41.9%). High-risk patients were 24.7% by Sokal, 10.8% by EURO, and 11.8% by EUTOS risk scores. The raw incidence increased with age from 0.39/100 000/year in people 20-29 years old to 1.52 in those >70 years old, and showed a maximum of 1.39 in Italy and a minimum of 0.69 in Poland (all countries together: 0.99). The proportion of Sokal and Euro score high-risk patients seen in many countries indicates that trial patients were not a positive selection. Thus from a clinical point of view the results of most trials can be generalized to most countries. The incidences observed among European countries did not differ substantially. The estimated number of new CML cases per year in Europe is about 6370.
PrintDisplayed: 27/5/2024 05:04